A third US company has released study results showing its coronavirus vaccine is safe and elicits an immune response.
Novavax, Inc. released Phase 1 data Tuesday from 131 volunteers showing that after two doses of the vaccine, participants developed neutralizing antibodies at levels more than four times higher on average than the antibodies developed by people who had recovered from Covid-19. Neutralizing antibodies fight off the virus that causes Covid-19.
"That's good. That's really encouraging," said Novavax president Dr. Gregory Glenn.
The vaccine also induced a response from T-cells, a type of immune cell, according to an analysis of 16 randomly selected volunteers, the report stated.
The report has been submitted to a medical journal, but has not yet been reviewed by scientists outside of Novavax or published.